Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma

Table 3 Comparison of all-cause adverse events between the combination group and monotherapy group following propensity score matching, n (%)

Variable	Combination group (n = 72)	Monotherapy group (n = 72)
Patients with an adverse event from any cause	48 (66.6)	35 (48.6)
Grade 1 or 2 event	34 (47.2)	28 (38.9)
Grade 3 event	12 (16.7)	7 (9.7)
Grade 4 event	2 (2.7)	0
Grade 5 event	0	0
Dose interruption of PD-(L)1 inhibitors	5 (6.9)	0
Dose interruption of molecular targeted therapies	7 (9.7)	0
Dose reduction of PD-(L)1 inhibitors	8 (11.1)	0
Dose reduction of molecular targeted therapies	12 (16.6)	0

PD-(L)1: Programmed cell death (ligand) 1.